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Abstract
Background: Deep vein thrombosis (DVT) is a challenging condition for clinician in all specialities. 
Prognosis after vein thromboembolism is worse and much worse after pulmonary embolism. 
Anticoagulant is the mainstay therapy for deep vein thrombosis, but there is still slow thrombus 
resolution even with the use of optimal anticoagulant. The use of intravenous thrombolytic agents 
is one of the methods to signifi cantly lyse thrombus. Since there is increasing risk of bleeding 
with the use of the agents, indication is limited. Lumbrokinase is oral thrombolytic that may give 
signifi cant thrombus lyses without increasing the risk of bleeding for deep vein thrombosis. This 
study was conducted to compare single warfarin therapy with combination of  lumbrokinase and 
warfarin for thrombus resolution in deep vein thrombosis patients.
Methods: This study was a randomized open labeled trial comparing deep vein thrombosis patients 
using single warfarin therapy group to group using combination lumbrokinase and warfarin. 22 
patients meet the inclusion and exclusion criteria. Patients were followed for 30 days and in the 
end of the trial, evaluation using vascular Doppler ultrasonography was done. Chi-square analysis 
was used to compare the outcome between two therapy groups.
Results: In this trial, group therapy with added lumbrokinase to warfarin yielded a tendency 
toward better thrombus resolution compared to group with single warfarin therapy (58.3% vs. 
30%, p=0.231). 
Conclusion : Added therapy with lumbrokinase to warfarin may give better thrombus resolution as 
compared to single warfarin therapy, although there is no signifi cant difference between groups.
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Introduction
Deep vein thrombosis (DVT) is a challenging 
condition for all clinicians. It could happen in 
every vein system area with main attention to the 
development of fatally complication known as 
pulmonary embolism (PE).1 The mainstay therapy 
of DVT is to cease the development of thrombus 
and  prevent recurrence and thromboemboli 
complication. All of these goals are achieved using 
anticoagulants.2 The use of thrombolytic agent in 
DVT has not yet being examined. Thrombolytic 
agents could produce faster thrombus lyses 
and recanalyzation of occluded veins, as well 
as to reduce symptoms. Although the improved 
outcome, there were only few studies that 
have been conducted to show better clinical 
improvement by using thrombolytic agents 
compared to anticoagulants.3
Lumbrokinase is oral thrombolytic agents 
introduced by Mihara in 1991. Lumbrokinase 
came from Lumbricidae families of earthworm 
that has properties to dissolute fi brin and activate 
plasminogen. Active substance from these 
earthworms that had been characterized and 
known to have thrombolytic properties was serine 
protease enzyme group. This enzyme was known 
to have thrombolytic and fi brinogenolytic properties, 
lower blood viscosity and degrade thrombus. 4 With 
all of these properties, lumbrokinase could be a 
promising agent in patients with DVT.
Lumbrokinase addition to warfarin therapy 
may increase thrombus resolution in DVT 
patients. Warfarin takes 5 days to achieve optimal 
anticoagulation, in the other hand, lumbrokinase 
can achieve fi brinolytic within hours and could 
be given orally. The use of anticoagulant only 
accomplishes 6% thrombus lyses in acute 
illiofemoralis and femoralis DVT within 10 days 
therapy. Thrombus propagation can also be 
found in 40% of patients that had already used 
heparin. 5
The aim of this study is to compare the 
effi cacy of lumbrokinase and warfarin and single 
warfarin in DVT patients. A primary outcome 
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is thrombus resolution in both treatments and 
a secondary outcome is safety parameters in 
lumbrokinase and warfarin therapy.
Method
This open-labeled randomized control 
trial has been conducted in RSUP Dr. Sardjito 
Yogyakarta from Mei to December 2014 with DVT 
patients as study subjects. Inclusion criteria are: 
(1) DVT patients diagnosed by Doppler vascular 
ultrasonography, (2) patients age between 30 to 
70 years and (3) patients agree to participate in 
this study by signing informed consents. Exclusion 
criteria are: (1) patients with increased level of 
aminotransferase enzymes above twice the upper 
limit, (2) patients with chronic kidney disease 
with creatinine clearance time <30 mL/minute 
(Cockroft-Gault criteria), (3) antiplatelet use, 
(4) bleeding abnormalities and active bleeding, 
(5) pregnancy and lactating, (6) uncontrolled 
hypertension (systolic blood pressure>180 mmHg 
and diastolic blood pressure>110 mmHg), and 
(7) critically ill patients or patients with severe 
infection.
Dependent variable in this study is resolution 
of thrombus. Independent variable is the use of 
lumbrokinase and warfarin and single warfarin 
therapy. Confounding variabless are the onset 
of symptoms, the coagulation functions and the 
underlying clinical condition, such as cancer or 
heart failure.
Study Protocol
Patients with DVT who met inclusion criteria 
would sign an informed consent to participate in 
this study and be admitted to DVT treatment in 
study protocol. Subjects were randomized after 
fi ve days of i.v UFH and initial warfarin therapy. 
Subjects were then divided into two groups, either 
lumbrokinase and warfarin therapy group or single 
warfarin group.
Anamnesis on history of the disease and 
risk factor, physical examination, thorax photo, 
laboratory examinations (complete blood count, 
renal function test, liver function test, fasting 
Figure 1.Study protocol
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blood glucose, HbA1c in patient with history of 
diabetes mellitus, complete cholesterol workup, 
and coagulation function) were done in all of the 
subjects. Subjects were randomized in the end of 
the fi fth day to determine which therapy they would 
be admitted, using combination of lumbrokinase 
and warfarin or single warfarin therapy until the 
end of the fourth week.
Coagulation functions were monitored in the 
fi rst fi ve days of warfarin initiation and intravenous 
(i.v) unfractionated heparin therapy. The monitoring 
in the fi rst fi ve days consisted of routine 3, 6, 12 
and 24 hour aPTT check and in interval of 24 hours. 
International normalized ratio (INR) was evaluated in 
day three for dose adjustment to achieve target INR 
2-3. Afterward, coagulation function were measured 
in the end of the fourth week.
Doppler vascular ultrasonography was 
conducted initially to determine the diagnosis of 
DVT and in the end of the study to evaluate the 
effect of the therapy. The locations of the thrombus, 
diameter thrombus, compression ultrasonography 
and fl ow pattern were items that were taken in 
the test.
Resolution of the thrombus was measured 
using lytic thrombus criteria by Protack et al 
6 Outcome of the study was divided into two 
categories, without improvement and resolution. 
Without improvement was defi ne as propagation 
of thrombus to other vein segment or if thrombus 
was seen in the same segment with <50% change 
in diameter of thrombus. Resolution was defi ne 
if there was decreasing diameter of thrombus ≥ 
50% or if thrombus could not be visualized in the 
same vein segment.
Subjects were asked to report any adverse 
reactions such as allergy or any minor or major 
bleeding. Any major bleeding or severe adverse 
reaction would halt lumbrokinase or warfarin 
therapy.
Statistical analysis
Continuous data between groups were 
compared by unpaired T test. Categorical data 
between groups were compared with chi-square 
test. In the 2x2 tables, Fisher exact test was used 
when Chi-Square test requirements were not 
staisfi ed. Multivariate analyses were performed 
to examine whether cancer and heart failure 
infl uenced the resolution of thrombus. Analysis 
considered signifi cant when the p value <0.05. 
Data analysis was performed with SPSS version 
22. Approval from the Medical and Health 
Research Ethics Committee, Faculty of Medicine, 
University of Gadjah Mada, was given before the 
research was conducted. 
Table1. Baseline characteristic of the subjects between groups
Variables
Warfarin and 
Lumbrokinase
(n=12)
Warfarin 
(n=10)
P value
Age (mean,years) 50.67±12.62 53.9±13.3 0.567
Gender, n(%)
 Male 
 Female 
8 (36%)
4 (18%)
2 (9%)
8 (36%)
0.029
Onset of symptom, n(%)
Acute (< 2 weeks)
Chronic (>2 weeks)
7(46.7%)
8(53.3%)
3(42.9%)
4(57.1%)
1.00
BUN, mean±SB, (mg/dL) 13.7±8.52 10.27±4.21 0.252
Creatinine, mean ±SB, (mg/dL) 1.19±0.79 0.83±0.36 0.210
SGOT, mean±SB (U/L) 32.6 ± 13.1 24.1±8.9 0.097
SGPT, mean±SB (U/L) 32.0 ± 12.7 18.0 ± 9.0 0.009
Coagulation function, mean±SB
aPTT
PPT
INR
35.7 ± 5.8
15.4 ± 2.2
1.10 ± 0.20
44.6 ± 29.7
16.0 ± 1.8
1.19 ± 0.15
0.317
0.500
0.396
Underlying condition, n(%)
Imobilization 
Malignancies 
Heart failure
Post operative
Hormonal contraceptive 
2(17%)
1(8%)
0
1(8%)
1(8%)
5(50%)
5(50%)
3(30%)
0
0
0.095
0.029
0.041
0.350
0.350
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Results
Baseline characteristic of the subjects
This study was conducted in Mei-December 
2014 in Cardiovascular Care Unit RSUP Dr. 
Sardjito, Yogyakarta. A total of 25 subjects met 
inclusion criteria but there were drop out in 3 
subjects due to warfarin allergy (n=1) and loss 
of follow up (n=2). The baseline characteristic of 
subjects were presented in table 1.
Deep vein thrombus resolution
Doppler vascular ultrasonography were 
performed in 22 subjects during initial examination 
and post therapy. The results of the examination 
showed thrombus in femoral veins (12 subjects 
(54.5%)), popliteal veins (9 subjects (40.9%) and 
subclavian vein (1 subject (4.5%)). There were 
no signifi cant difference between two treatment 
groups in regard of the location of the thrombus 
(p=0.529).  Figure 2 showed the percentage of 
thrombus location. 
Figure 2.  Distribution of thrombus location among 
subjects
Mean diameter of the thrombus in initial 
diagnosis was 3 mm (range: 1-12 mm) with mean 
diameter in lumbrokinase and warfarin group was 
4.75 ± 3.84 mm and mean diameter in single 
warfarin group was 3.6 ± 1.89 mm. There was no 
signifi cant difference in initial thrombus diameter 
between two therapy groups (p=0.399). Mean 
diameter of thrombus during evaluation was 2.5 
mm (range: 0-12 mm) with thrombus resolution 
was 44.5% (range: 0-100%). 
Figure 3 showed the percentage of subjects 
with thrombus resolution compared to those 
without improvement. In both treatment groups 
there were 45.5% subjects with resolution and 
54.5% subjects without improvement.
Figure 3. Percentage of subjects with resolution 
and without improvement in both 
treatment groups
Mean thrombus resolution in lumbrokinase 
and warfarin group was 53.2% ± 39.0% and 
in single warfarin group was 30.0% ± 40.0% 
(p=0.203). Mean percentage of thrombus resolution 
in lumbrokinase and warfarin group was better as 
compared to its resolution in single warfarin group, 
although there was no signifi cant difference. Figure 
4 showed the mean thrombus resolution between 
two therapy group.
Figure 4.  Mean percentage of thrombus resolution 
in single warfarin group compared to 
lumbrokinase and warfarin group
The comparison between the number of 
subjects with resolution in lumbrokinase and 
warfarin group and single warfarin group was 
analyzed using Chi-square. Table 2 showed the 
comparison of resolution between two therapy 
groups. 
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Table 2. showed that percentage number 
of subjects with resolution were tend to be larger 
in lumbrokinase and warfarin group (70.0% vs 
30.0%), although there was no significance 
difference (p=0,231). Odds ratio in resolution of 
the thrombus using lumbrokinase and warfarin 
was 3.26 (95% CI 0.55-19.25), however no 
signifi cant.
Safety parameter
In this study, we conducted assessments of 
bleeding effect in both treatment groups. During 
the study, there was no report on adverse event 
in all of study subjects.
All subjects received warfarin with therapeutic 
target of INR 2-3. An INR target was not achieved 
in as many as 72.7% subjects although the 
evaluation of INR was done routinely and warfarin 
dosing was adjusted. There were 66.7% of 
subjects (n=8) with INR below the target, in whom 
the evaluation showed without improvement of 
thrombus. Figure 5 showed comparison of INR in 
patients without thrombus improvement. 
The use of lumbrokinase in clinical trial 
was limited and there was no study that measure 
laboratory parameter in patients with DVT. In 
this study we measured renal function test, 
liver function test and coagulation function post 
lumbrokinase and warfarin therapy and single 
warfarin therapy. Table 3 showed comparison in 
two treatment groups before and after therapy.
Table 2.  Comparison between between subjects with resolution in lumbrokinase and warfarin 
group to single warfarin group
Categories Warfarin + Lumbrokinase Warfarin p value OR 95% CI
Resolution (%) 58.3 30.0 0.231 3.26 0.55-
19.25Without improvement (%) 41.7 70.0
Table 3.  Renal function test, liver function test and coagulation function in two 
treatment groups before and after therapy
Variable Before therapy After therapy p value
Warfarin
BUN (mg/dL)
Creatinin (mg/dL) 
SGOT (U/L)
SGPT (U/L) 
APTT (detik)
PPT (detik)
INR
10.3±4.2
0.8±0.4
24.1±8.9
18.0±9.0
44.7±29.7
16.3±1.8
1.2±0.1
19.6±7.1
1.0±0.5
23.4±12.2
16.4±8.3
38.9±18.4
21.9±17.6
1.8±1.7
0.012
0.032
0.674
0.401
0.646
0.440
0.114
Warfarin and lumbrokinase
BUN (mg/dL)
Creatinin (mg/dL) 
SGOT (U/L)
SGPT (U/L) 
APTT (detik)
PPT (detik)
INR
13.7±8.5
1.19±0.79
32.6±13.1
32.0±12.7
35.7±5.8
15.4 ± 2.1
1.12 ± 0.2
12.6±8.5
0.9±0.2
29.4±15.2
26.4±17.0
40.1±7.1
23.1 ± 6.5
2.0 ± 0.8
0.170
0.722
0.182
0.054
0.050
0.020
0.010
Figure 5. Comparison of INR value in without 
improvement group 
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Discussion
In this study there were 10 male subjects 
(40%) and 12 female subjects (48%) with mean age 
of 52.14 years (SD± 12.7 years). In patients > 40 
years old there were increased risk of having DVT 
which is consistent with the study fi ndings.7 Thrombus 
distribution in this study was mainly in proximal vein, 
mostly in femoral vein. In distal thrombus, symptoms 
were rarely meet. Proximal vein involvement was as 
many as 89% in the previous study of 189 patients 
with symptomatic DVT.8
Mean thrombus resolution in this study was 
44.5%, which was similar with fi nding in the studies 
by Killewich et al. and Caprini et al. that stated there 
were 45% until 56% of thrombus resolution within 
30 days post anticoagulation therapy.9,10 In this 
study, the percentage of subjects with resolution 
were larger in lumbrokinase and warfarin therapy 
group compared to single warfarin group although 
there were no sinifi cant difference. This could 
be attributd to the lyses effect of thrombus by 
lumbrokinase that was added to standard warfarin 
therapy. The use of anticoagulant alone did not 
give thrombus lyses property nor breakdown of 
the clot. The breakdown of the clot depends on 
the thrombolytic ability in every individual. Thus, 
lumbrokinase which works by degrading thrombus 
directly could help in speed thrombus lyses 
process and enhanced thrombus resolution.
Jin et al. showed increased level of tissue 
plasminogen activator (tPA) in patients with 
cerebral infarction that were given lumbrokinase. 
Hence, in this study increasing tPA level could be 
the mechanism that enhanced thrombolytic effect 
in patients with DVT. 11 Recanalization of thrombus 
in DVT patient was seen in case report by Kaligis 
who determined clinical improvement and full 
recanalization in right common femoralis  veins 
after lumbrokinase use in 14 days. 12  This study 
showed the potentially better thrombus resolution 
in adding lumbrokinase to standard warfarin 
therapy as the mainstay therapy for DVT.
There were no significant difference in 
subjects with resolution between two therapy 
groups in this study. This could be cause by 
the small number of subjects obtained in this 
study and the short observation time. Also in our 
study there were subjects with malignancy and 
heart failure. Heart failure had 0.67 odds ratio to 
achieve thrombus resolution (95% CI: 0.01-9.19). 
Malignancies that occured  in 5 subjects (23%) 
were all failed to show thrombus resolution. Hence 
malignancies were one of the condition that cause 
failure to achieve thrombus resolution.
In malignancies patient, residual thrombus that 
were shown with CUS abnormalities were higher 
compared to non malignancies. As many as 23% of 
patients with malignancies had CUS normalization 
in 6 months compared to 53% patients in non 
malignancies patients.13 This condition could be due 
predisposing factor that stayed even after therapy 
which is prothrombotic condition in malgnancies and 
the diffi culty of management of anticoagulant due to 
diffi culty of monitoring. This condition was caused by 
changes of nutritional status, multiple drugs therapy 
and change of metabolism.13,14 Heart failure was also 
a predictor of vein thromboembolism. But,studies on 
residual thrombus in heart failure patients were only 
few. Piazza et al. studied 1822 heart failure patients 
with thromboemboli and showed recurrency DVT 
in 37 patients due to interaction of multiple factors 
such as immobilization, acute infection, chronic lung 
disease, stroke and other condition.15
In safety parameter there were no bleeding 
side effect observed during the study. Assessment 
of hepatic and renal function were also showed 
that adding lumbrokinase to warfarin therapy 
did not alter the hepatic and renal function. This 
fi ndings were consistent with fi nding by Gayatriet 
al. in healthy subjects. 16
The difference between this study and other 
study that showed no difference in aPTT, PPT 
and INR value could be to the effect of the use of 
warfarin. By observing therapy effect of warfarin 
to aPTT,PPT and INR also the increasing aPTT 
value in lumbrokinase therapy, we conclude that 
increased coagulation function observed post 
therapy of warfarin and lumbrokinase could be 
due to interaction betwee two therapies.
Study Limitation
In this study, the sample size was smaller 
than expected, also there were difficulty in 
achieving target INR in both groups. Other 
limitation of this study was the short observation 
time that  cause  inability to measure full resolution 
of thrombus.
Conclusion 
In this study the percentage of subjects 
that had thrombus resolution were larger in 
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lumbrokinase and warfarin group as compared 
to thrombus resolution in single warfarin group, 
although there were no signifi cant difference. 
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